Tereos : -29% decline in EBITDA for 2024/25 and very cautious guidance for 2025/26, with leverage that could reach 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria: Q1 2025 results reassuring despite ongoing liquidity concerns|Isabel Marant: despite a further improvement in the topline, EBITDA fell again in Q1|Tough 2025 results, withdrawal of 2026 targets, Q1 2026 revenue expected to drop by 20%, and new CFO|
Tereos : publication d’une baisse de -29% de l’EBITDA en 2024/25 et guidance très prudente pour 2025/26, avec un levier qui pourrait aller jusqu’à 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria : un T1 2025 rassurant même si la liquidité reste critique|Isabel Marant : malgré une nouvelle amélioration de la topline, l’Ebitda est à nouveau en baisse au T1|Résultats 2025 difficiles, retrait des objectifs 2026, CA T1 2026 attendu en baisse org....
European equity markets weakened in October following multiple disappointments across the earnings season. The impending US election, the outcome of which is highly uncertain according to the polls, may also have prompted some traders to adopt a cautious stance. Sovereign long rates rose sharply, particularly in the US, on the back of macro indicators likely to provide arguments to the most hawkish of central bankers. All eyes are now on the November 5 elections and their repercussion...
Les marchés actions européens ont fléchi en octobre après les nombreuses déceptions sur la saison des résultats. L’approche de l’élection US, très incertaine selon les sondages, pourrait également avoir poussé à la prudence certains opérateurs. Les taux longs souverains ont nettement remonté, en particulier aux Etats-Unis, sur la base d’indicateurs macro susceptibles de donner des arguments aux plus faucons des banquiers centraux. Tous les yeux sont désormais rivés sur le scrutin du 5...
>Outperform rating maintained – target price reduced to € 13.0 (vs € 13.6) - BBVA’s performance in Q3/9M 2024 remains solid (operationally/balance sheet-wise) and lends weight to the 2024 guidance. We have raised our 2024-2026 net income forecasts by 2% on average given more favourable prospects on revenues (NII, commissions) and despite a slightly more conservative stance on the CoR. We maintain our Outperform rating on the stock in light of the bank’s solid prospect...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.